 low-molecular-weight heparinoid warfarin prophylaxi deep-vein thrombosi patient fractur hip prospect random trial random prospect trial low-molecular-weight heparinoid org lomoparan warfarin efficaci safeti deep-vein thrombosi patient treat fractur hip group patient org dose unit twelv hour ninth postop day seventh postop day warfarin regimen group warfarin drug admiss evalu patient warfarin prothrombin time one-half time control level deep-vein thrombosi scan imped plethysmographi phlebographi compress ultrasonographi deep-vein thrombosi cent patient org twenty-eight cent patient warfarin advers reaction differ group major complic patient group drug time bleed patient warfarin signific differ intraop loss blood requir transfus low-molecular-weight heparinoid org safe conveni effect antithrombot agent prevent venou thrombosi oper fractur hip